Effect of carprofen and/or CIDR on pregnancies per AI (P/AI) 14 days after artificial insemination (AI) in lactating cows were investigated. Following detection of corpus luteum (CL) by ultrasonography (USG) 14 days after AI, cows (n=853) were randomly allocated to CARP (carprofen, 1.4 mg/kg; Rimadyl®XL), CIDR (progesterone, 1.38g, for seven days), CARP+CIDR and CONT (control) groups. CL was re-determined with USG 21 days after AI to monitored the maintenance of CL. Rates of maintenance of CL did not differed among CARP (79.6% [168/211]), CIDR (86.0% [196/228]), CARP+CIDR (80.0% [172/215]) and CONT (74.9% [149/199]) groups; however, the interaction effect of treatment by body condition score (BCS) at AI (P<0.05) were existed. In this matter, among cows with BCS≤2.5, chances of maintenance of CL was lower in CONT (70.7%, [111/157]) group compared to those in CARP (81.7%, [125/153]), CIDR (83.6%, [153/183]) and CARP+CIDR (80.1%, [129/161]) groups. Whereas, among cows with BCS>2.5, chances of maintenance of CL were lower in CARP (74.1%, [43/58]) and CARP+CIDR (79.6%, [43/54]) groups compared to those in CONT (90.5%, [38/42]) and CIDR (95.6%, [43/45]) groups. For the P/AI at 28-32 days after AI, there was no difference among CARP (48.8% [103/211]), CIDR (50.9 [116/228]), CARP+CIDR (47.4% [102/215]) and CONT (44.7% [89/199]) groups. Pregnancy losses between 28-32 and 55-60 days did not differ among CARP (3.9%, [4/103]), CIDR (4.3%, [5/116]), CARP+CIDR (5.9%, [6/102]) and CONT (6.7%, [6/89]) groups. However, there was a significant (P<0.05) interaction effect of treatment by the number of services on pregnancy losses. In this regard, pregnancy losses were higher in cows inseminated thrice and four or more times in CONT (11.8% and 16.7%) group compared to those in CARP (0% and 4.8%), CIDR (0% and 6.9%), CARP+CIDR (0% and 11.1%); respectively. Consequently, no effects of carprofen or CIDR around pregnancy recognition on P/AI were observed despite a higher maintenance rate of CL in lactating cattle. Furthermore, fewer pregnancy losses in cows following three or more services could indicate the beneficial carry-over effects of carprofen and/or CIDR administration around maternal recognition of pregnancy.
The objective of the study was to investigate the effect of pre-synchronisation on the occurrence of the oestrus and pregnancy rate after fixed time artificial insemination (FTAI) in synchronised ewes during the anoestrous season. Kivircik ewes (n = 84) were randomly assigned to one of the two treatment groups with (PRE; n = 42) or without (SYN; n = 42) pre-synchronisation. In the SYN group, the ewes were subjected to a 7-d short-term protocol (P4 insertion-6d-PGF2α-1d-P4 removal + eCG). In the PRE group, the same short-term protocol as in the SYN group was applied with 7 days apart for a pre-synchronised synchronisation protocol. A cervical FTAI was performed with fresh semen at 54 h after sponge removal. At the beginning of the synchronisation protocol, the oestrous response (66.7% vs. 0.0%) and cyclicity rates (64.3% vs. 14.3%) based on progesterone (P4) were higher in the PRE group compared to those in the SYN group, respectively (P < 0.01). However, the oestrous response after synchronisation was lower within 96 h (57.1% vs. 95.2%; P < 0.01) in the PRE group compared to that in the SYN group. Although the pregnancy rate after the FTAI was significantly (P < 0.05) lower in the PRE group (14.3%) than the SYN group (35.7%), the overall pregnancy rate after natural mating was not different (95.2%) between the groups. In conclusion, the pre-synchronisation decreased the oestrous response leading to a lower pregnancy rate after the FTAI in the synchronised ewes during the anoestrous season. Thus, attention should be paid to two consecutive administrations of eCG in a pre-synchronisation and synchronisation protocol in ewes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.